One possible explanation is that tumours can adapt to CDK4/6 inhibitors if ESR1 signalling is not correctly suppressed, but, when considering the lack of consensus regarding ESR1 status and CDKi sensitivity, further studies are needed. The gene discussed is ESR1; the disease is neoplasm.